IBS Treatment Market Regional Analysis:
North America Market Insights
North America industry is expected to hold largest revenue share of 36.4% by 2035, owing to the presence of advanced healthcare facilities and ongoing advancements in the pharma sector. The presence of early adopters in the region is driving the sales of innovative irritable bowel syndrome drugs.
The U.S. IBS treatment market is forecasted to rise at substantial CAGR till 2035. The strong presence of key market players is fuelling the sales of irritable bowel syndrome drugs in the country. In Canada, the increasing prevalence of irritable bowel syndrome issues is anticipated to boost the market growth during the forecasted period. The Canadian Digestive Health Foundation reveals that the prevalence rate of irritable bowel syndrome is around 18% in the country.
Asia Pacific Market Insights
Asia Pacific irritable bowel syndrome treatment market is expected to increase at a fast pace during the forecasted period owing to the increasing spending on healthcare infrastructure, expanding pharmaceutical manufacturing companies, and growing cases of obesity leading to IBS issues. India, Japan, South Korea, and China are the most profitable economies for irritable bowel syndrome drug manufacturers.
The high investments in healthcare infrastructure development projects and favorable government policies on drug production are generating profitable opportunities for irritable bowel syndrome therapeutic solution producers in India. The country is emerging as a medical tourism hub owing to the presence of cost-effective and advanced technologies and skilled expertise for various treatments. For instance, the local government is focusing on increasing its Pradhan Mantri Bhartiya Jan Aushadhi Kendras to 10,500 by March 2025. This is set to boost the sales of IBS drugs in the country.
